Raymond James raises Fulgent Genetics stock price target to $36 on strong performance
Kevin Christopher Siebert, SVP, General Counsel & Secretary at Viavi Solutions Inc (NASDAQ:VIAV), sold 11,148 shares of common stock on November 3, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at prices ranging from $17.29 to $17.32, with the total value of the transaction amounting to $192,748.
Following the transaction, Siebert directly owns 73,450 shares of Viavi Solutions Inc. common stock.
In other recent news, Viavi Solutions reported robust fiscal first-quarter results, with revenue reaching $299 million, reflecting a 25.6% increase year-over-year. This performance surpassed both management guidance and consensus estimates of $294 million. The company also posted adjusted earnings per share of $0.15, exceeding analyst projections of $0.13. The Network and Service Enablement segment was a key contributor, generating $216 million in revenue, driven by strong demand in the data center ecosystem. Additionally, Viavi’s acquisition of Inertial Labs partially aided the revenue growth. Analyst firms have taken note of these results; Stifel raised its price target for Viavi Solutions to $18, maintaining a Buy rating, while B.Riley upgraded the stock from Neutral to Buy, citing growth in artificial intelligence and data centers. Viavi also issued strong guidance, further boosting investor confidence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.